Docetaxel is used for the treatment of hormone-refractory metastatic prostate cancer, non-small cell lung cancer, and operable node-positive breast cancer. It was first introduced by Sanofi Aventis Us Llc in its drug Taxotere on May 14, 1996. Other drugs containing Docetaxel are Docefrez, Docivyx, Docetaxel. 24 different companies have introduced drugs containing Docetaxel.

Docetaxel Patents

Given below is the list of patents protecting Docetaxel, along with the drug name that holds that patent and the company name owning that drug.

Drug Used in	Drug Patent Number	Drug Patent Title	Drug Patent Expiry	Drug Owner
Docetaxel	US10842770	Non-aqueous taxane pro-emulsion formulations and methods of making and using the same	Aug 07, 2031	Shilpa
Docetaxel	US8940786	Non-aqueous taxane nanodispersion formulations and methods of using the same	Sep 30, 2033	Shilpa
Docetaxel	US9308195	Non-aqueous taxane formulations and methods of using the same	Sep 30, 2033	Shilpa
Docetaxel	US9763880	Non-aqueous taxane formulations and methods of using the same	Sep 30, 2033	Shilpa
Docivyx	US10398785	Pharmaceutical compositions containing taxane-cyclodextrin complexes, method of making and methods of use	Mar 14, 2036	Avyxa Holdings
Taxotere	US5438072	Taxoid-based compositions	Nov 22, 2013 (Expired)	Sanofi Aventis Us
Taxotere	US5438072 (Pediatric)	Taxoid-based compositions	May 22, 2014 (Expired)	Sanofi Aventis Us
Taxotere	US5698582	Compositions containing taxane derivatives	Jul 03, 2012 (Expired)	Sanofi Aventis Us
Taxotere	US5698582 (Pediatric)	Compositions containing taxane derivatives	Jan 03, 2013 (Expired)	Sanofi Aventis Us
Taxotere	US5714512	Compositions containing taxane derivatives	Jul 03, 2012 (Expired)	Sanofi Aventis Us
Taxotere	US5714512 (Pediatric)	Compositions containing taxane derivatives	Jan 03, 2013 (Expired)	Sanofi Aventis Us
Taxotere	US5750561	Compositions containing taxane derivatives	Jul 03, 2012 (Expired)	Sanofi Aventis Us
Taxotere	US5750561 (Pediatric)	Compositions containing taxane derivatives	Jan 03, 2013 (Expired)	Sanofi Aventis Us

Add above patents to watchlist

A patent's expiry date may change depending upon legal activities going on that patent. Critical activities like abandoning of a patent, term extension of a patent or amendment of its claims can increase or decrease the life of a patent hence affecting its expiry date and in turn affecting the generic launch date of that drug. Tracking these ongoing activities on a patent application helps to keep an eye on the latest developments in the patent process of the drug which can give an idea of how early a drug's generic could be available. The next section provides a list of recent legal activities on Docetaxel's patents.

Latest Legal Activities on Docetaxel's Patents

Given below is the list recent legal activities going on the following patents of Docetaxel.

Event	Date	Patent/Publication
Today's Critical Events
Payment of Maintenance Fee, 4th Year, Large Entity	08 May, 2024	US10842770
Payment of Maintenance Fee, 8th Year, Large Entity	27 Sep, 2023	US9308195
Payment of Maintenance Fee, 8th Year, Large Entity	13 Jul, 2022	US8940786
Post Issue Communication - Certificate of Correction	18 May, 2021	US10842770
Email Notification	13 May, 2021	US10842770
Mail Pet Dec Routed to Certificate of Corrections Branch	12 May, 2021	US10842770
Mail-Record a Petition Decision of Granted for Patent Term Adjustment after Issue	12 May, 2021	US10842770
Record a Petition Decision of Granted for Patent Term Adjustment after Issue	11 May, 2021	US10842770
Pet Dec Routed to Certificate of Corrections Branch	11 May, 2021	US10842770
Adjustment of PTA Calculation by PTO	11 May, 2021	US10842770

Coming Soon

Patent Strength Analyzer

Will this be useful for you?

YesNo

Thank you for your response 🥳